Health & Beauty

In order to further support countries in the fight against the new crown pneumonia epidemic and comprehensively expand international cooperation in vaccines, the Ministry of Commerce and other four departments issued an announcement on June 22 The four vaccines of the Institute of Products Research Co., Ltd. are included in the list of new crown vaccine products available for export.

Li Xinggan, Director of the Foreign Trade Department of the Ministry of Commerce, said that the four vaccines included in the list have been approved for listing in China, and the two vaccines of its Chinese medicine Zhongsheng Beijing Company and Beijing Kexing Zhongwei Company have been listed in the WHO. Organize an emergency use list. The above-mentioned vaccine products have been vaccinated on a large scale in China and have been approved for use in hundreds of countries around the world. The list will also be dynamically adjusted in a timely manner based on the approval of the State Food and Drug Administration.

"In order to ensure the quality and safety of vaccine products and improve trade efficiency, we support the Chinese vaccine manufacturers listed in the list to organize exports on their own, focusing on increasing product supply and stabilizing market expectations, so that all countries, especially developing countries, can use it. A vaccine is available and affordable." Li Xingqian said.

According to the previously announced new crown vaccine production capacity, Sinopharm China Biotech's annual production capacity reached 3 billion doses, Beijing Kexing Zhongwei Company disclosed that the annual production capacity of new crown vaccine exceeded 2 billion doses, and the national production capacity of Cansino is expected to reach 700 million doses this year. In addition, Zhifei Bio will produce 500 million doses of vaccines this year. Kangtai Bio will have an annual production capacity of 200 million doses of inactivated vaccines, which can be increased to 600 million doses. The annual output of inactivated vaccines of the Institute of Biology of the Medical Academy will reach 500 million to 1 billion doses. . The total production capacity of my country's new crown vaccine in 2021 is expected to exceed 7 billion doses.

Tan Yadi, deputy secretary-general of the China International Association for the Promotion of Science and Technology, told the Securities Daily reporter that the main cost of vaccines comes from the research and development side, while the production side, such as vaccine training and packaging materials, has low cost requirements, thanks to my country The competitive advantage of the production supply chain, if enterprises need to increase production capacity, there is not much pressure. It's just that the global vaccine production capacity is expected to exceed 15 billion doses this year, and different countries and regions have different acceptance of vaccines. Therefore, due to market supply and demand considerations, domestic vaccine manufacturers will be relatively cautious in expanding production capacity.

Tao Lina, a former vaccine expert of the Shanghai Centers for Disease Control and Prevention, said in an interview with a reporter from the Securities Daily that there is often a certain gap between the actual output and production capacity of vaccine manufacturers, which provides room for temporary production increases. From the perspective of domestic vaccine demand and external export supply, the production capacity of domestic vaccines can meet the current market demand, and companies have the ability to adjust production capacity at any time according to market demand.

Tao Lina said: "The emergence of variant strains of the new crown virus has also raised concerns that it may reduce the effectiveness of the new crown vaccine. At present, vaccine manufacturers have two strategies for this. One is to design vaccines based on the variant strain and vaccinate the variant strain separately. Or add it to the original vaccine; the other is to enhance the persistence of antibodies by strengthening the needle. The prevention and control of the epidemic does not only rely on vaccines, but also adhere to effective public health safety measures, because our country has already done so in this field. It is relatively complete, so the demand for vaccines is relatively stable."

Due to the hot sales of vaccines, the market is very concerned about vaccine concept stocks. For example, the leader of the vaccine sector, Zhifei Biology, has increased by nearly 200% since March 2020, and its current market value has reached 284 billion yuan; Cansino has increased since its listing on the Science and Technology Innovation Board in August 2020. Reached 260%, the current market value reached 187.3 billion yuan.

Taolina said that the contributions made by Chinese and foreign new crown vaccine manufacturers to combat the new crown virus are obvious to all. Regarding the performance and market performance of new crown vaccine manufacturers, both at home and abroad are unanimously optimistic.

Gong Tao, chairman of Shenzhen Zhongjin Huachuang Fund, told the "Securities Daily" reporter that biological vaccine research and development companies are high-risk and high-yield industries, so capital will prefer leading companies in the industry. For example, CanSino's R&D team comes from a global biopharmaceutical giant, and it is the industry's top in terms of R&D team and industry experience. Therefore, it is more recognized by capital and the stock market performs better.

Gong Tao said: “China’s vaccine research and development industry is on the rise, and the domestic new crown vaccine has become an important international business card for Chinese vaccine companies, indicating that my country’s vaccine research and development capabilities have reached the world’s leading level. Because most of the global vaccine market share has been lost by Pfizer, Pfizer, Under the control of European and American biopharmaceutical companies such as GSK, Merck and Sanofi, Chinese vaccine companies need to win word of mouth through technology and quality, and gradually increase their international influence with the help of the domestic new crown vaccine."